Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Recombinant Adeno-associated virus vectors (rAAV) are widely used for gene delivery and multiple naturally occurring serotypes have been harnessed to target cells in different tissues and organs including the brain. Here, we provide a detailed and quantitative analysis of the transduction profiles of rAAV vectors based on six of the most commonly used serotypes (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9) that allows systematic comparison and selection of the optimal vector for a specific application. In our studies we observed marked differences among serotypes in the efficiency to transduce three different brain regions namely the striatum, hippocampus and neocortex of the mouse. Despite the fact that the analyzed serotypes have the general ability to transduce all major cell types in the brain (neurons, microglia, astrocytes and oligodendrocytes), the expression level of a reporter gene driven from a ubiquitous promoter varies significantly for specific cell type / serotype combinations. For example, rAAV8 is particularly efficient to drive transgene expression in astrocytes while rAAV9 appears well suited for the transduction of cortical neurons. Interestingly, we demonstrate selective retrograde transport of rAAV5 along axons projecting from the ventral part of the entorhinal cortex to the dentate gyrus. Furthermore, we show that self-complementing rAAV can be used to significantly decrease the time required for the onset of transgene expression in the mouse brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“AAV5 transduces only granular cells”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“AAV2 is restricted to pyramidal and granular cells”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They express the transgene within days or weeks and can reach full expression levels after 4-6 weeks in vivo [20,21].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the promoter was cytomegalovirus (CMV), AAV9 has robust tropism for neurons and displays high expression levels in the hippocampus (Aschauer et al., 2013).”
From Hippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease (2024) · cites this paper as Aschauer et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340 · cited 1×
“We choose the hippocampus as this is an intensely studied brain region for its role in memory formation and spatial navigation [20], the striatum for its role in the coordination of movements and neurological diseases such as Parkinson’s disease [21,22] and finally the neocortex as the part of the brain specific to ma…”
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572 · cited 1×
“However, in situ expression data does not indicate selective expression of PDGFR alpha or beta in the entorhinal cortex that could explain specific retrograde labeling of entorhinal neurons in a simple manner [67].”
BackgroundInterneurons of the neocortical inhibitory system
Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., & Wu, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1519 · Cited by 2,954 · cited 1×
“We chose gamma-aminobutyric acid (GABA) as a marker for the major population of inhibitory neurons in the central brain [27], oligodendrocyte transcription factor 2 (Olig2) as a marker for oligodendrocytes [28], ionized calcium-binding adapter molecule 1 (Iba1) as a marker for microglia [29] and glial fibrillary acidi…”
MethodA resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex
Taniguchi, H., He, M., Wu, P., Kim, S., Paik, R., Sugino, K., Kvitsani, D., Fu, Y., Lu, J., Lin, Y., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.026 · Cited by 1,828 · cited 2×
“To determine what population of long-range projecting neurons is selectively labeled by AAV5 we performed injections of rAAV5 in a transgenic mouse strain in which GABA-ergic interneurons are labeled by the red fluorescent reporter protein tdTomato [26,50].”
BackgroundMethodLearning and Memory Functions of the Basal Ganglia
Packard, M. G., & Knowlton, B. J. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142937 · Cited by 1,717 · cited 1×
“We choose the hippocampus as this is an intensely studied brain region for its role in memory formation and spatial navigation [20], the striatum for its role in the coordination of movements and neurological diseases such as Parkinson’s disease [21,22] and finally the neocortex as the part of the brain specific to ma…”
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 3×
“Indeed, significant differences in transduction efficacy of various serotypes for particular tissues and cell types have been described [11,12,16-19].”
BackgroundAmygdala circuitry mediating reversible and bidirectional control of anxiety
Tye, K. M., Prakash, R., Kim, S.-Y., Fenno, L. E., Grosenick, L., Zarabi, H., Thompson, K. R., Gradinaru, V., Ramakrishnan, C., & Deisseroth, K. (2011) · Nature · doi:10.1038/nature09820 · Cited by 1,289 · cited 1×
“In recent years many studies have taken advantage of recombinant viral vectors derived from Adeno-associated virus (AAV) as a gene delivery tool [3-5].”
BackgroundInduction of neurogenesis in the neocortex of adult mice
Magavi, S. S., Leavitt, B. R., & Macklis, J. D. (2000) · Nature · doi:10.1038/35016083 · Cited by 1,216 · cited 1×
“In addition, all sections were stained with the pan-neuronal marker neuronal nuclei (NeuN) [31] and the DNA stain DAPI that highlights nuclei.”
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs
Olson, J. K., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3916 · Cited by 1,215 · cited 1×
“This stimulus is known to induce an acute inflammatory response [36] and shows that our protocol to detect microglia is sensitive to tissue undergoing an immune reaction and that this reaction is limited locally to one hemisphere (Figure 4).”
BackgroundMonosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons
Wickersham, I. R., Lyon, D. C., Barnard, R. J. O., Mori, T., Finke, S., Conzelmann, K.-K., Young, J. A. T., & Callaway, E. M. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.033 · Cited by 1,187
Cited by
Items 301–400 of 557
Peeters, L. M., Missault, S., Keliris, A., & Keliris, G. A. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14885 · Cited by 13
Koshimizu, Y., Isa, K., Kobayashi, K., & Isa, T. (2021) · Gene Therapy · doi:10.1038/s41434-020-00212-y · Cited by 13
Mehlman, M. L., Winter, S. S., & Taube, J. S. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00144.2018 · Cited by 14
“…however, the rAAV5 virus can also infect axon terminals located at the injection site, resulting in the retrograde transport of the virus from these axons to their associated cell bodies, ultimately producing EYFP expression within these cell bodies (Aschauer et al. 2013; Chamberlin et al. 1998).”
BackgroundInfluentialTsou, J., Lee, S. M., Chiang, C.-Y., Yang, Y.-J., Guo, F.-Y., Ni, S.-Y., & Yau, H. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2114-22.2023 · Cited by 12
Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice
Verma, A., Ray, A., Bapat, D., Diwakar, L., Kommaddi, R. P., Schneider, B. L., Hirsch, E. C., & Ravindranath, V. (2020) · Movement Disorders · doi:10.1002/mds.28190 · Cited by 12
“Thus, the viral transduction of shRNA-Grx1 would result in Grx1 downregulation in all cell types in the SNpc, presumably not at similar levels.(37) The neurodegeneration of TH-positive neurons in the SNpc could, therefore, have been influenced by the altered redox homeostasis caused by global Grx1 downregulation acros…”
BackgroundEmerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies
von Jonquières, G., Rae, C. D., & Housley, G. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661857 · Cited by 12
Cabrera, G. T., Meijboom, K. E., Abdallah, A., Tran, H., Foster, Z. W., Weiss, A., Wightman, N., Stock, R. E., Gendron, T. F., Gruntman, A. M., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00418-w · Cited by 12
“H1 promoter driving the expression of the arti fi cial microRNA followed by a CBA promoter driving eGFP a PolyA tail.”
Lu, W.-H., Chang, T.-T., Chang, Y., Liu, Y.-H., Lin, C.-H., Suen, C., Hwang, M., & Huang, Y. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01061-2 · Cited by 11
A brief guide for gene delivery to the brain using adeno-associated viral vectors
Han, S., Yang, E. M., & Hur, E. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100189 · Cited by 15
The functional role of locus coeruleus microglia in the female stress response
Smiley, C. E., Pate, B. S., Bouknight, S. J., Harrington, E. N., Jasnow, A. M., & Wood, S. K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02971-9 · Cited by 14
AAV-Mediated CRISPRi and RNAi Based Gene Silencing in Mouse Hippocampal Neurons
Deutsch, M., Günther, A., Lerchundi, R., Rose, C. R., Balfanz, S., & Baumann, A. (2021) · Cells · doi:10.3390/cells10020324 · Cited by 12
“While rAAV2 is considered to transduce a broad range of cell types and tissues, rAAV9 is more efficient in transducing neurons [40].”
BackgroundPeter, M., Aschauer, D. F., Rose, R., Sinning, A., Groessl, F., Kargl, D., Kraitsy, K., Burkard, T. R., Luhmann, H. J., Haubensak, W. E., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244038 · Cited by 12
“The effective transduction of neurons by rAAV5 [85] and the selection of large nuclei for photolabeling are factors contributing to the strong bias”
BackgroundSelf-citationOptogenetics 2.0: challenges and solutions towards a quantitative probing of neural circuits
Altahini, S., Arnoux, I., & Stroh, A. (2023) · Biological Chemistry · doi:10.1515/hsz-2023-0194 · Cited by 12
Advances and Challenges in Gene Therapy for Alzheimer’s Disease
Morroni, F., & Caccamo, A. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230783 · Cited by 8
Optogenetic Control of Neural Circuits in the Mongolian Gerbil
Keplinger, S., Beiderbeck, B., Michalakis, S., Biel, M., Grothe, B., & Kunz, L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00111 · Cited by 11
“More than 12 naturally occurring subtypes have been described, which display distinct tropisms for certain cell types (Burger et al., 2004; Zincarelli et al., 2008; Aschauer et al., 2013).”
BackgroundVogels, T., Vargová, G., Brezováková, V., Quint, W. H., & Hromádka, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200047 · Cited by 11
“AAV9serotypespreadsveryefficientlythrough-outtheCNSand,therefore,isoneofthecommonly usedAAVserotypesforinfectinglargenumbersof neuronsinlargerareas[45,46].”
Szablowski, J. O., & Harb, M. (2020) · Journal of Visualized Experiments · doi:10.3791/61352 · Cited by 11
Minnig, M. A., Park, T., Sanchez, M. E., Cottone, P., & Sabino, V. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.787362 · Cited by 11
“After 3 weeks of viral incubation, a time-course commonly used in rodent brain tissue to ensure sufficient viral infection (Reimsnider et al., 2007; Aschauer et al., 2013), 30 min self-administration sessions resumed for a total of 14 post-injection sessions (2 weeks).”
BackgroundTargeted tPA overexpression in denervated spinal motor neurons promotes stroke recovery in mice
Gan, X., Chopp, M., Xin, H., Wang, F., Golembieski, W., Lü, M., He, L., & Liu, Z. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20901686 · Cited by 12
“Our results are consistent with a recent study that AAV5 is particularly efficient for selective retrograde axonal transport in mouse brain.(32) As the safest viral vector system, with the first approval of AAV-mediated gene therapy by the European Medicines Agency in 2012 (GlyberaR ), and by the US Food and Drug Admi…”
ResultGene therapy using Aβ variants for amyloid reduction
Park, K., Wood, C. A., Li, J., Taylor, B. C., Oh, S.-W., Young, N. L., & Jankowsky, J. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.026 · Cited by 12
Gene therapy for Leber hereditary optic neuropathy
Battista, M., Carelli, V., Bottazzi, L., Bandello, F. M., Cascavilla, M. L., & Barboni, P. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2359015 · Cited by 10
“For human gene therapy strategy, AAV2, AAV8 and AAV9 were selected for their specific tropism; in particular, AAV9 demonstrates the capability to cross the blood-brain barrier, thus resulting valuable for the central nervous system [38].”
BackgroundMorais, R. D. V. S., Sogorb-González, M., Bar, C., Timmer, N. C., van der Bent, M. L., Wartel, M., & Vallès, A. (2022) · Cells · doi:10.3390/cells11172748 · Cited by 13
“The propensity for AAV transport within the nervous system is, in part, serotype dependent [45], with AAV5 demonstrating more efficient axonal transport than other serotypes such as”
BackgroundLi, H., Chen, Z., Shen, Y., Xiong, T., Chen, A., Chen, L., Ye, Y., Jiang, Q., Zhang, Y., Sun, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05571-3 · Cited by 14
“It was reported [44] that AAV type 9 spread in the hippocampus of mice and had a higher infection efficiency compared with other AAV serotypes.”
BackgroundWu, Y., Han, Z., Duan, M., Jiang, L., Tian, T., Jin, D., Wang, Q., & Xu, F. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210118111657 · Cited by 10
Biodistribution of Adeno-Associated Virus Serotype 5 Viral Vectors Following Intrathecal Injection
Pflepsen, K. R., Peterson, C. D., Kitto, K. F., Riedl, M. S., McIvor, R. S., Wilcox, G. L., Vulchanova, L., & Fairbanks, C. A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00252 · Cited by 10
Fujita, W., Uchida, H., Kawanishi, M., Kuroiwa, Y., Abe, M., & Sakimura, K. (2022) · Biomolecules · doi:10.3390/biom12101471 · Cited by 10
“According to the previous research related to the in vivo virus genome introduction, the viral genome has been reported to remain episomal in the nucleus but maintains sustained expression in terminally differentiated cells for several weeks to months [15,16].”
MethodKawano, T., Zhou, J., Anwar, S., Salah, H., Dayal, A. H., Ishikawa, Y., Boetel, K., Takahashi, T., Sharma, K., & Inoue, M. (2023) · Nature Communications · doi:10.1038/s41467-023-39518-x · Cited by 10
Matsuyama, M., Ohashi, Y., Tsubota, T., Yaguchi, M., Kato, S., Kobayashi, K., & Miyashita, Y. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423963112 · Cited by 12
“Reports about retrograde transduction by AAV vector appear inconsistent; it has been reported as weak or ineffective in some cases (51, 52) and effective in others (44, 45).”
ResultR-Ras contributes to LTP and contextual discrimination
Darcy, M. J., Jin, S., & Feig, L. A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.010 · Cited by 10
“AAV9 is known to preferentially infect neurons over non-neuronal cells (Aschauer et al., 2013).”
BackgroundDisease Modification Through Trophic Factor Delivery
Savolainen, M. H., Emerich, D. F., & Kordower, J. H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_24 · Cited by 11
Képiró, M., Várkuti, B. H., & Davis, R. L. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.09.021 · Cited by 10
Counsell, J. R., Karda, R., Diaz, J. F. A., Carey, L., Wiktorowicz, T., Buckley, S. M. K., Ameri, S., Ng, J., Baruteau, J., Almeida, F., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.006 · Cited by 12
“It is often desirable to target discrete brain regions with gene transfer vectors, but we have shown that LV and AAV vectors spread extensively from an injection site and give widespread expression after neonatal injection, meaning that anatomical accuracy is lost without a region-specific promoter.(48) This constitut…”
Parallel Organization of Cerebellar Pathways to Sensory, Motor, and Associative ForebrainPreprint
Pisano, T. J., Dhanerawala, Z. M., Kislin, M., Bakshinskaya, D. E., Engel, E. A., Lee, J., de Oude, N. L., Hansen, E. J., Venkataraju, K. U., Hoebeek, F. E., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3810000 · Cited by 14
Enbar, T., Hickmott, J. W., Siu, R., Gao, D., Flores, E. G., Smart, J., Casabuenas, D. L., Faiz, M., & Morshead, C. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-79124-5 · Cited by 10
Yu, J.-H., Nam, B.-G., Kim, M., Pyo, S., Seo, J. H., & Cho, S. (2021) · Genes · doi:10.3390/genes12050712 · Cited by 9
Ball, J., Frank, M. G., Green-Fulgham, S. M., & Watkins, L. (2024) · Brain, behavior, and immunity · doi:10.1016/j.bbi.2024.03.005 · Cited by 9
Adeno-associated viral serotypes differentially transduce inhibitory neurons within the rat amygdala
de Solis, C. A., Hosek, M. P., Holehonnur, R., Ho, A., Banerjee, A., Luong, J. A., Jones, L. E., Chaturvedi, D., & Ploski, J. E. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.023 · Cited by 11
“AAV5 has been shown to function superior or similarly to some other serotypes in the striatum and substantia nigra (Aschauer et al., 2013; McFarland et al., 2009; Taymans et al., 2007) and in the hippocampus (Aschauer et al., 2013).”
Palma-Chavez, A., Konar-Nié, M., Órdenes, P., Maurelia, F., Elizondo-Vega, R. J., Oyarce, K., López, S., Rojas, J., Steinberg, X. P., García, M. D. L. Á., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00647 · Cited by 9
“These results suggest that DAGLα inhibition could reduce the production of 2-AG in tanycytes and, therefore, block the usual response of these neurons to lengthy fasting conditions (33, 37).”
BackgroundKosten, L., Emmi, S. A., Missault, S., & Keliris, G. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.938665 · Cited by 9
“In this case, a viral construct is intracranially injected and the cellular transduction and expression of the DREADDs is determined by the viral vector’s serotype (of genome and capsid) and promoter gene (Aschauer et al., 2013).”
BackgroundZelena, D., Demeter, K., Haller, J., & Balázsfi, D. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000361 · Cited by 9
“For example, in the hippocampus, 2 μl is often used (Kiyota et al., 2015; Alves et al., 2016), whereas in smaller brain areas, 50–80 nl with a 20 nl/min flow rate is more common (Aschauer et al., 2013).”
BackgroundMethodInfluentialGene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies
Hosseini, K., Fallahi, J., Tabei, K., & Razban, V. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3887 · Cited by 8
“113 The results of clinical research have shown that one of the best methods of transferring gene therapy agents into the body is intravenous (i.v.) injection, because by using this method, enzyme defects in the whole body are corrected.”
Long-term, high-resolution in vivo calcium imaging in pigeons
Nimpf, S., Kaplan, H. S., Nordmann, G. C., Cushion, T. D., & Keays, D. A. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100711 · Cited by 12
Luchicchi, A., Pattij, T., Viaña, J. N. M., de Kloet, S. F., & Marchant, N. J. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.109004 · Cited by 9
Herdt, A. R., Peng, H. C., Dickson, D. W., Golde, T. E., Eckman, E. A., & Lee, C. W. (2023) · Genes · doi:10.3390/genes14081517 · Cited by 8
Yamakawa, W., Yasukochi, S., Tsurudome, Y., Kusunose, N., Yamaguchi, Y., Tsuruta, A., Matsunaga, N., Ushijima, K., Koyanagi, S., & Ohdo, S. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad482 · Cited by 10
“This was probably due to the inability of AAV vectors to express transgenes in microglia (34).”
BackgroundYang, J., Prouvot, P.-H., Stroh, A., & Luhmann, H. J. (2017) · Neuromethods · doi:10.1007/978-1-4939-7417-7_8 · Cited by 9
Widening spinal injury research to consider all supraspinal cell types: Why we must and how we can
Blackmore, M. G., Batsel, E., & Tsoulfas, P. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113862 · Cited by 8
“Many AAV serotypes exist, with unique capsid structures that confer distinct tropism and patterns of intraneuronal transport (Aschauer et al., 2013; Bohlen et al., 2020; Srivastava, 2016).”
BackgroundBackhaus, R. G., Fu, T., Backhaus, H., & Stroh, A. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.101010 · Cited by 11
“Viral gene transfer provides the foundation for regional and cellular specificity of indicator or opsin protein expression (Aschauer et al., 2013).”
BackgroundGene therapy for GM1 gangliosidosis: challenges of translational medicine.
Hayward, C., Patel, H. C., Manohar, S., & Lyon, A. R. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.02.28 · Cited by 8
“In the mouse, for example, direct injection of AAV in to the brain demonstrated that different serotypes (1, 2, 5, 6, 8 and 9) varied in their transduction efficiency in different regions of brain (striatum, neocortex and hippocampus) (11).”
BackgroundAdeno-Associated Viral Vector Delivery to the Enteric Nervous System: A Review.
Gombash, S. E. (2015) · PubMed · doi:10.21307/pdj-2015-029 · Cited by 13
Fortuna, M. G., Hüer, J., Guo, H., Gruber, J., Gruber-Dujardin, E., Staiger, J. F., Scherberger, H., Treue, S., & Gail, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-67752-6 · Cited by 10
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 8
“Various AAV serotypes exhibit specific tissue tropism, notably for lung epithelial cells, cardiac cells, neurons, and skeletal muscle cells, enabling targeted gene delivery to specific tissues (Aschauer et al., 2013; Bish et al., 2008; Blankinship et al., 2004; Halbert et al., 2001).”
Multiplex viral tropism assay in complex cell populations with single-cell resolution
Keng, C. T., Guo, K., Liu, Y., Shen, K., Lim, D. S., Lovatt, M., Ang, H.-P., Mehta, J. S., & Chew, W. L. (2022) · Gene Therapy · doi:10.1038/s41434-022-00360-3 · Cited by 7
Motor Control of Distinct Layer 6 Corticothalamic Feedback Circuits
Martinetti, L. E., Autio, D. M., & Crandall, S. R. (2024) · eNeuro · doi:10.1523/eneuro.0255-24.2024 · Cited by 8
“We chose AAV2 because the diffusion is more con fi ned than other serotypes (Aschauer et al., 2013; Haery et al., 2019), allowing for more precise vM1 targeting and limiting lateral spread (Martinetti et al., 2022).”
Witteveen, I. F., & Balmer, T. S. (2024) · eNeuro · doi:10.1523/eneuro.0391-24.2024 · Cited by 7
“…McFarland et al., 2009; Blits et al., 2010; Hutson et al., 2012), while other studies demonstrate a lack of ef fi cacy by AAV2 (Taymans et al., 2007; Aschauer et al., 2013; Watakabe et al., 2015) or higher ef fi cacy of other serotypes (Paterna et al., 2004; Mason et al., 2010; Holehonnur et…”
Palchaudhuri, S., Lin, B.-X., Osypenko, D., Wu, J., Kochubey, O., & Schneggenburger, R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115320 · Cited by 7
Salegio, E. A., Cukrov, M., Lortz, R., Green, A., Lambert, E., Copeland, S., Gonzalez, M., Stockinger, D. E., Yeung, J. M., & Hwa, G. G. C. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.163 · Cited by 7
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fang, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 8
“PEG‐enhanced rAAV expression in vitro We chose rAAV serotype 9 (rAAV9) to evaluate the effects of PEG additive on transgene expression because it has been widely used for gene delivery in the mammalian brain [37], especially well-suited for the transduction of neurons [38], and is currently being evaluated in clinical…”
MethodKinsky, N. R., Vöröslakos, M., Ruiz, J. R. L., de Jong, L. W., Slager, N., McKenzie, S., Yoon, E., & Diba, K. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102570 · Cited by 7
Unlocking the potential of adeno-associated virus in neuroscience: a brief review
Minetti, A. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09521-6 · Cited by 10
“These include the natural tropism of AAV serotypes [54, 55], which may not match the target cell type, as well as the presence of pre-existing neutralizing antibodies in the host that can inhibit vector entry [56–58].”
BackgroundP4‐694: RETROMER REPLETION WITH AAV9‐VPS35 RESTORES ENDOSOMAL FUNCTION IN THE MOUSE HIPPOCAMPUS
Qureshi, Y. H., Berman, D. E., Klein, R. L., Patel, V. M., Simoes, S., Kannan, S., Cox, R., Waksal, S. D., Stevens, B., Petsko, G. A., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.058 · Cited by 7
Kunisawa, K., Hatanaka, N., Shimizu, T., Kobayashi, K., Osanai, Y., Mouri, A., Shi, Q., Bhat, M. A., Nambu, A., & Ikenaka, K. (2020) · Molecular Brain · doi:10.1186/s13041-020-00698-y · Cited by 7
Kolpakova, J., van der Vinne, V., Giménez‐Gómez, P., Le, T., You, I., Zhao-Shea, R., Velázquez‐Marrero, C., Tapper, A. R., & Martin, G. E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.742207 · Cited by 10
Hunter, J. E., Molony, C. M., Bagel, J. H., O’Donnell, P. A., Kaler, S. G., & Wolfe, J. H. N. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.007 · Cited by 8
Ex Vivo Optogenetic Dissection of Fear Circuits in Brain Slices
Bosch, D., Asede, D., & Ehrlich, I. (2016) · Journal of Visualized Experiments · doi:10.3791/53628 · Cited by 9
Delayed Treatment with Histone Deacetylase Inhibitors Promotes Stroke Recovery
Kannangara, T. S., & Vani, M. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2615-17.2017 · Cited by 7
“HDAC2 expression is present in neurons, astrocytes, and oligodendrocytes (for review, see Gräff and Tsai, 2013), and the AAV plasmid used by Lin et al. (2017) has a notably high transduction efficiency for cortical glia (Aschauer et al., 2013).”
BackgroundGilman, T. L., Dutta, S., Adkins, J. M., Cecil, C. A., & Jasnow, A. M. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.09.010 · Cited by 8
Serotype-based evaluation of an optogenetic construct in rat cortical astrocytes
Balachandar, L., Borrego, D., & Diaz, J. R. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.027 · Cited by 7
Common AAV gene therapy vectors show nonselective transduction of ex vivo human brain tissue
McGinnis, J. P., Ortiz‐Guzman, J., Guevara, M. C., Mallannagari, S., Belfort, B. D. W., Bao, S., Srivastava, S., Morkas, M., Ji, E., Addison, A. P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101494 · Cited by 6
Treatment of Huntington’s disease with a pan-HTT-targeting CRISPR nuclease
Tan, K., Siller, D. D. B., Xiong, A. Y., Wang, A. X. A., McCallister, T. X., Mummadi, S., John, L. A. S., Lee, T. K., Carrillo, A., Renshaw, D. G., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.038 · Cited by 8
Sternberg, Z. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03684-2 · Cited by 6
“It is noteworthy that the AAV2 vector used for the transfer of the functional hDDC gene has high degree of tropism to neurons, and low degree of tropism to microglia and astrocytes [120].”
Viral vectors for gene delivery to the central nervous system
Ingusci, S., Hall, B. L., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00001-0 · Cited by 8
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Deborah, R., Cavedon, A., Siddiqui, S., Rice, L., Finn, P. F., et al. (2024) · Cells · doi:10.3390/cells13231979 · Cited by 8
Fiber Photometry Analysis of Spontaneous Dopamine Signals: The Z -Scored Data Are Not the Data
Wallace, C. W., DiMarco, E. K., Slinkard, C. Y., Shaughnessy, R., Holleran, K. M., Centanni, S. W., Lapish, C. C., & Jones, S. R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00078 · Cited by 8
WONOEP appraisal: Molecular and cellular imaging in epilepsy
Lillis, K. P., Dulla, C. G., Maheshwari, A., Coulter, D. A., Módy, I., Heinemann, U., Armbruster, M., & Žiburkus, J. (2015) · Epilepsia · doi:10.1111/epi.12939 · Cited by 8
Thiele, N., Hildebrandt, K. J., & Köppl, C. (2020) · Current Research in Neurobiology · doi:10.1016/j.crneur.2020.100001 · Cited by 7
“Experiments with mice demonstrated different expression levels, onset times and different infection rates for a range of organs and tissues, after injection into the tail vein or brain, respectively (Aschauer et al., 2013; Zincarelli et al., 2008).”
BackgroundInfluentialBrown, B. L., Zalla, R. M., Shepard, C. T., Howard, R. M., Kopechek, J. A., Magnuson, D. S. K., & Whittemore, S. R. (2021) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2021.635921 · Cited by 6
“, 2004; Srivastava, 2016), (2) AAV2 has minimal volumetric spread at the injection site (Burger et al., 2004; Aschauer et al., 2013), (3) unlike other serotypes, AAV2 has little potential for retrograde transduction (Hollis et al.”
BackgroundDeutsch, M., Stegmayr, C., Balfanz, S., & Baumann, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136699 · Cited by 6
“As established in a previous study [21], recombinant Adeno-associated viruses (rAAVs) of serotype 9, which is considered transducing neurons with high specificity [22], were generated to deliver hcn2specific constructs (sh2) to target cells.”
MethodSehara, Y., Hayashi, Y., Ohba, K., Uchibori, R., Urabe, M., Inutsuka, A., Shimazaki, K., Kawai, K., & Mizukami, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.106 · Cited by 6
“4 These features make AAVs ideal vectors to transduce genes into the CNS.”
Rescue of GM3 synthase deficiency by spatially controlled, rAAV-mediated ST3GAL5 delivery
Yang, H., Brown, R. H., Wang, D., Strauss, K. A., & Gao, G. (2023) · JCI Insight · doi:10.1172/jci.insight.168688 · Cited by 6
“AAV serotype 9 (AAV9) can cross the BBB and transduce neural tissues, but it also efficiently transduces multiple peripheral tissues such as liver, skeletal muscle, and heart (16, 17).”
BackgroundTranslating preclinical models of neuronal ceroid lipofuscinosis: progress and prospects
Nelvagal, H. R., & Cooper, J. D. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1360182 · Cited by 6
Fomenko, A., Lee, D. J., McKinnon, C., Lee, E. J., de Snoo, M. L., Gondard, E., Neudorfer, C., Hamani, C., Lozano, A. M., Kalia, L. V., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00463 · Cited by 7
“After injection into brain tissue, AAVs are able to induce long-term expression of desired genes in both neuronal and non-neuronal cells largely dictated by viral serotype (Taymans et al., 2007; Mitchell et al., 2010; Aschauer et al., 2013).”
BackgroundResultOptical control of purinergic signaling
Wang, T., Ulrich, H., Semyanov, A. V., Illés, P., & Tang, Y. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09799-2 · Cited by 6
Cao, W., Tan, Z., Berackey, B. T., Nguyen, J. K., Brown, S. R., Du, S., Lin, B., Ye, Q., Seiler, M. J., Holmes, T. C., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101054 · Cited by 7
Lippert, M., Takagaki, K., Weidner, T., Brocka, M., Tegtmeier, J., & Ohl, F. W. (2018) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-812028-6.00017-3 · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Rao, D., Kwak, G., Wang, H., Eberhart, C. G., Hanes, J. S., & Suk, J. S. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00799 · Cited by 5
Gene Therapy for Central Nervous System in Duchenne Muscular Dystrophy
Vaillend, C., Zarrouki, F., & Vacca, O. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_24 · Cited by 5
Kakava-Georgiadou, N., Bullich‐Vilarrubias, C., Zwartkruis, M. M., Luijendijk, M. C. M., Garner, K. M., & Adan, R. A. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47417-9 · Cited by 6
Chen, Y., Liu, L., Li, M., Yao, E., Hao, J., Dong, Y., Zheng, X., & Liu, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.153 · Cited by 6
Modulation of GABAergic neurons in acute epilepsy using sonogenetics
Phan, T.-N., Fan, C., Wang, H., Liu, H., Lin, Y., & Yeh, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.029 · Cited by 6
Functional analysis of mutations endowing rAAV2-retro with retrograde tracing capacity
Zhang, Y., Wang, J., Li, J., Chen, Y., Sun, J., Lu, Z., Li, Y., & Liu, T. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136746 · Cited by 4
Skoven, C. S., Tomasevic, L., Kvitsiani, D., Pakkenberg, B., Dyrby, T. B., & Siebner, H. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.968839 · Cited by 4
“We can however not exclude that callosal neurons projecting from the contralateral hemisphere might have taken the viral construct up retrogradely (Taymans et al., 2007; McFarland et al., 2009; Mason et al., 2010; Aschauer et al., 2013; Rook et al., 2021), which in turn potentially could result in antidromic contamina…”
BackgroundHansen, A. K. K., Dubik, M., Marczynska, J., Ojha, B., Nistal‐Villán, E., González‐Aseguinolaza, G., Arengoth, D. S., Owens, T., & Khorooshi, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911292 · Cited by 4
“A study by Aschauer et al. (2013) demonstrated that AAV8 effectively transduces cells of the CNS, particularly astrocytes [14].”
BackgroundChen, S., He, B., Singh, S., & Martin, N. P. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_6 · Cited by 6
Potenza, M. L., Blankvoort, S., Carvalho, M. M., Grimstvedt, J. S., Maria, V. D., Moan, K., Nair, R. R., Flatset, M. S., Zhang, Q., Thomas, L. F., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1274174 · Cited by 4
Oligodendrocytes, the Forgotten Target of Gene Therapy
Ozgür-Gunes, Y., Stunff, C. L., & Bougneres, P. F. (2024) · Cells · doi:10.3390/cells13231973 · Cited by 4
Development of In Vivo Imaging Tools for Investigating Astrocyte Activation in Epileptogenesis
Kostoula, C., Pascente, R., Ravizza, T., McCown, T., Schoch, S., Vezzani, A., Becker, A., & van Loo, K. V. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0660-x · Cited by 5
Liu, G., Li, H., Cull, G. A., Wilsey, L. J., Yang, H., Reemmer, J., Shen, H., Wang, F., Fortune, B. A., Bui, B. V., et al. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.1.26 · Cited by 4
“Although the viral delivery system using an AAV8 serotype has been reported to have high specificity for retinal astrocytes, 28,51 our Western blot results showed that there was approximately a 40% downregulation of the total retinal Cx43 protein compared with control eyes, suggesting incomplete…”
BackgroundMethodEngineered AAV13 Variants with Enhanced Transduction and Confined Spread
Luo, N., #169, E. L. R., cai, Y., Han, Z., Sui, X., Yuan, W., Zhang, Z., Guo, H., Wang, J., Lin, K., et al. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2023.355 · Cited by 7
Metadata
- Authors
- Aschauer, D. F., Kreuz, S., & Rumpel, S.
- Affiliations
- Research Institute of Molecular Pathology (AT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Rumpel, Simon
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-27
- Volume
- 8
- Issue
- 9
- Pages
- e76310
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3785459
- OpenAlex
- W2015741711
- Cited by
- 522
- References
- 68
- Citations by year
- 2026: 26 · 2025: 31 · 2024: 47 · 2023: 44 · 2022: 40 · 2021: 49 · 2020: 44 · 2019: 57 · 2018: 45 · 2017: 42 · 2016: 42 · 2015: 34 · 2014: 20 · 2013: 1
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, AAV serotypes, AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, transduction efficiency, axonal transport, retrograde transport, self-complementary AAV, gene delivery to the brain, striatum, hippocampus, neocortex, astrocytes, cortical neurons, microglia, oligodendrocytes, entorhinal cortex, dentate gyrus, reporter gene expression
- MeSH terms
- Dependovirus, Analysis of Variance, Animals, Axonal Transport, Brain, Cloning, Molecular, Gene Expression Regulation, Genetic Vectors, Microscopy, Fluorescence, Organ Specificity, Transduction, Genetic, Gene Transfer Techniques, Transgenes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.